Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients.
Robert Charles Newton
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Peggy A Scherle
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Kevin Bowman
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Xiangdong Liu
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Gregory Lawrence Beatty
No relevant relationships to disclose
Peter J O'Dwyer
Research Funding - Incyte
Thomas Gajewski
Consultant or Advisory Role - Incyte; Incyte
Research Funding - Incyte; Incyte
Jill Bowman
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Richard Schaub
Employment or Leadership Position - Incyte
Lance Leopold
Employment or Leadership Position - Incyte
Stock Ownership - Incyte